Reneuron Share News (RENE)
RENE Share
RENE Share
RENE Share
RENE Share
RENE
RENE Share
RENE Level 2
RENE Live
RENE Broker
RENE Directors
RENE Financial
RENE
RENE Short
RENE
Last checked at -
Wed, 14th Jul 2021 15:15
ReNeuron Group PLC - Bridgend, Wales-based developer of cell-based therapeutics - Hires Barbara Staehelin as senior independent non-executive director, starting immediately. Staehelin is a member of the Investment Committee at Swiss health insurance firm Assura Holding SA.
Current stock price: 103.89 pence
Year-to-date change: up 26%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Stem cell therapy company Reneuron Group has raised £68.4m to focus on its core product and nanomedicine cancer programme through to the first half of 2019, while final results highlighted progress of its other projects. A placing of £68.4m at a price of 5p per share saw star UK fund manager Neil Wo
Read more
Last checked at